NeurologyLive® Friday 5 — April 12, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 12, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Understanding Neurological Manifestations in Long COVID: Svetlana Blitshteyn, MD, FAAN

The director of Dysautonomia Clinic discussed neurological manifestations of Long COVID, such as headache, cognitive complaints, and sleep problems, and how they are similar to those seen with migraine comorbidities. [WATCH TIME: 5 minutes]

Understanding Neurological Manifestations in Long COVID: Svetlana Blitshteyn, MD, FAAN

2: Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of a newly published study highlighting extracellular vesicle-associated miRNA features that could be diagnostically informative of RBD in patients with Parkinson disease.

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

3: Possibilities and Realities With Early Intervention to Prevent Neurodevelopmental Disorders: Shafali Jeste, MD

The chief of neurology and co-director of the Neurological Institute at the Children’s Hospital Los Angeles discussed the hesitancy to enroll children with neurodevelopmental issues in early intervention trials without proven products or markers. [WATCH TIME: 5 minutes]

Possibilities and Realities With Early Intervention to Prevent Neurodevelopmental Disorders: Shafali Jeste, MD

4: NeuroVoices: Sharon Hesterlee, PhD, on Givinostat’s Approval for Duchenne Muscular Dystrophy, Future Prospects

In this week's NeuroVoices Q&A, the executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

NeuroVoices: Sharon Hesterlee, PhD, on Givinostat’s Approval for Duchenne Muscular Dystrophy, Future Prospects

5: Quality of Life in MG

In this Peer Exchange episode, experts in neurology highlight taking age and quality of life into consideration when approaching treatment of MG, as well as comment on the standard of care for patients.

Quality of Life in MG
Related Videos
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.